NCT04004819

Rituximab for HTLV-1-associated Myelopathy

Rituximab Therapy for the Patients With HTLV-1-associated Myelopathy

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: First Affiliated Hospital of Fujian Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Neuroprotective or anti-inflammatory strategies are invaluable in HTLV-1-associated myelopathy due to its rapid progression. We evaluated the efficacy of rituximab in patients with HTLV-1-associated myelopathy.

Conditions

• HTLV-1-associated Myelopathy

Interventions

Type	Name	Description
DRUG	Rituximab	A lower dosage of rituximab for HTLV-1-associated myelopathy

Timeline

• Start date: 2019-08-15
• Primary completion: 2023-07-01
• Completion: 2024-07-01
• First posted: 2019-07-02
• Last updated: 2022-04-19

Locations

1 site across 1 country: China